Drug intelligence / Profile preview

Eryfotona AK-NMSC (ISDIN)

Development stage
Unknown
Lead developer
ISDIN
Modality
Small Molecules, Recombinant Proteins and Enzymes, Liposomes → Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
Administration
Topical
01

Overview

Eryfotona AK-NMSC is a topical medical device designed for the prevention and adjunctive treatment of actinic keratosis (AK) and other forms of non-melanoma skin cancer (NMSC). Developed by ISDIN and distributed in the Nordic regions by Allderma, it combines high-spectrum UV protection (SPF 100+) with DNA Repairsomes. These Repairsomes contain photolyase, a DNA repair enzyme encapsulated in liposomes, which identifies and repairs cyclobutane pyrimidine dimers (DNA lesions) caused by UV radiation. By providing a physical barrier against further UV damage and actively repairing existing subclinical damage within the cancerization field, it reduces the risk of AK recurrence and progression.

Brand names
EryfotonaEryfotona AK-NMSCEryfotona SPF 100+Eryfotona Actinica
Other names
DNA Repairsomes
02

Targets

TP53 (Cellular Tumor Antigen p53 R175H)

Beyond the preview

Go deeper on Eryfotona AK-NMSC (ISDIN).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Eryfotona AK-NMSC (ISDIN).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call